文献速递核素与放射性配体治疗肿瘤 PET/CT

总肿瘤体积对177Lu标记PSMA肽治疗肿瘤与肾脏生物有效剂量的影响

The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides.
PubMed 文献 · J Nucl Med · 2018-02-01

本研究基于生理药代动力学模型拟合13例接受177Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者数据,模拟总肿瘤体积(TTV)0.1–10 L对肿瘤及危险器官生物有效剂量(BED)的影响。结果显示TTV从0.3 L增至3 L时,肿瘤、肾脏、腮腺及下颌下腺BED均下降,红骨髓BED升高。结论提示PSMA阳性肿瘤体积大的患者可安全给予更高活度和肽量以最大化肿瘤BED而不超过危险器官耐受BED。

要点

  • TTV从0.3 L增至3 L时,肿瘤BED由22±15降至11.0±6.0 Gy1.49,肾脏BED由6.5±2.3降至3.7±1.4 Gy2.5。
  • TTV从0.3 L增至3 L时,腮腺与下颌下腺BED均由约11.0降至约6.4 Gy4.5,红骨髓BED由0.17±0.05升至0.32±0.11 Gy15。
  • TTV>0.3 L患者的最佳肽量为273±136 nmol,最佳活度为10.4±4.4 GBq。

核心结论

  • 该模拟研究提示,PSMA阳性肿瘤体积大的患者可安全给予更高活度和肽量以最大化肿瘤BED而不超过危险器官耐受BED。

研究设计与样本

  • 生理药代动力学模型拟合13例接受177Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者数据,模拟TTV 0.1–10 L下的肿瘤、肾脏及唾液腺BED。

主要发现

  • TTV从0.3 L增至3 L时,肿瘤BED由22±15降至11.0±6.0 Gy1.49,肾脏BED由6.5±2.3降至3.7±1.4 Gy2.5。
  • TTV从0.3 L增至3 L时,腮腺BED由11.0±2.7降至6.4±1.9 Gy4.5,下颌下腺BED由10.9±2.7降至6.3±1.9 Gy4.5。
  • TTV从0.3 L增至3 L时,红骨髓BED由0.17±0.05升至0.32±0.11 Gy15。
  • TTV>0.3 L患者的最佳肽量为273±136 nmol,最佳活度为10.4±4.4 GBq。

关键数值与推荐

  • 肿瘤BED计算采用α/β=1.49 Gy,肾脏采用α/β=2.5 Gy,唾液腺采用α/β=4.5 Gy,红骨髓采用α/β=15 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to simulate the effect of prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) on the biologically effective doses (BEDs) to tumors and organs at risk in patients with metastatic castration-resistant prostate cancer who are undergoing 177Lu-PSMA radioligand therapy. Methods: A physiologically based pharmacokinetic model was fitted to the data of 13 patients treated with 177Lu-PSMA I&T (a PSMA inhibitor for imaging and therapy). The tumor, kidney, and salivary gland BEDs were simulated for TTVs of 0.1-10 L. The activity and peptide amounts leading to an optimal tumor-to-kidneys BED ratio were also investigated. Results: When the TTV was increased from 0.3 to 3 L, the simulated BEDs to tumors, kidneys, parotid glands, and submandibular glands decreased from 22 ± 15 to 11.0 ± 6.0 Gy1.49, 6.5 ± 2.3 to 3.7 ± 1.4 Gy2.5, 11.0 ± 2.7 to 6.4 ± 1.9 Gy4.5, and 10.9 ± 2.7 to 6.3 ± 1.9 Gy4.5, respectively (where the subscripts denote that an α/β of 1.49, 2.5, or 4.5 Gy was used to calculate the BED). The BED to the red marrow increased from 0.17 ± 0.05 to 0.32 ± 0.11 Gy15 For patients with a TTV of more than 0.3 L, the optimal amount of peptide was 273 ± 136 nmol and the optimal activity was 10.4 ± 4.4 GBq. Conclusion: This simulation study suggests that in patients with large PSMA-positive tumor volumes, higher activities and peptide amounts can be safely administered to maximize tumor BEDs without exceeding the tolerable BED to the organs at risk.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Begum NJ, Thieme A, Eberhardt N, et al. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides. J Nucl Med. 2018. PMID: 29419479. doi:10.2967/jnumed.117.203505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。